3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Squamous Cell Carcinoma of the Lung
1
Interventions
Cyclophosphamide
143
pembrolizumab
127
Nivolumab
116
Carboplatin
99
Dexamethasone
93
Rituximab
91
Paclitaxel
87
Gemcitabine
85
Lenalidomide
75
Cytarabine
74
Radiotherapy
73
Cisplatin
70
Bevacizumab
64
Etoposide
62
fludarabine phosphate
58
fludarabine
56
Ipilimumab
55
Docetaxel
54
Bortezomib
54
Prednisone
49
Doxorubicin
48
Temozolomide
47
Everolimus
46
Erlotinib Hydrochloride
46
Fluorouracil
44
Azacitidine
44
Capecitabine
43
Calcium Dobesilate
43
Filgrastim
42
Melphalan
41
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Has results
×
glembatumumab vedotin
×
Clear all
NCT02713828
2019-07-16
PrE0504
PrECOG, LLC.
Phase 1/2
Terminated
13 enrolled
12 charts